Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeCompareMounjaro vs Wegovy HD

Medication comparison

Mounjaro vs Wegovy HD

Mounjaro and Wegovy HD are both prescription medications (GIP/GLP-1 dual receptor agonist vs GLP-1 receptor agonist) used for Type 2 diabetes and Chronic weight management (BMI >=30, or >=27 with at least one weight-related comorbidity). The table below compares FDA-approved indications, dosing, weight-loss outcomes, side effects, contraindications, and current pricing — all sourced from the manufacturer prescribing information.

Find a provider for Mounjaro or Wegovy HD

Affiliate disclosure: we earn commission on signups. Editorial ranking stays independent.

This is general drug information, not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication.

Overview

PropertyMounjaroWegovy HD
Generic nametirzepatidesemaglutide 7.2 mg
Drug classGIP/GLP-1 dual receptor agonistGLP-1 receptor agonist
ManufacturerEli LillyNovo Nordisk
Brand namesMounjaroWegovy HD

Approved uses

PropertyMounjaroWegovy HD
Approved indicationsType 2 diabetesChronic weight management (BMI >=30, or >=27 with at least one weight-related comorbidity)

Dosing

PropertyMounjaroWegovy HD
Typical dosingTitrate to 15 mg (weekly SC injection)Titrate to 7.2 mg (weekly SC injection)

Side effects & warnings

PropertyMounjaroWegovy HD
Top side effectsNausea (29.6%), Diarrhea (23%), Vomiting (12.6%)Nausea (common), Vomiting (common), Diarrhea (common)
ContraindicationsPersonal or family history of medullary thyroid carcinoma (MTC); Multiple endocrine neoplasia syndrome type 2 (MEN 2); Hypersensitivity to semaglutide or any product component
Boxed warningYesYes

Special populations

PropertyMounjaroWegovy HD
PregnancyC — Discontinue at least 1 month before a planned pregnancy.Discontinue >=2 months before planned pregnancy

Storage

PropertyMounjaroWegovy HD
StorageRefrigerate before first use. After first use, room temperature up to 21 days.Refrigerate 2-8 C unopened. After first use: room temp up to 28 days.

Cost

PropertyMounjaroWegovy HD
Avg monthly cost$1023.04$1349.00

FDA boxed warning

Mounjaro: Risk of thyroid C-cell tumors. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Wegovy HD: Not established in humans, rodent C-cell tumor signal only; human relevance unknown per FDA label. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

Frequently asked

What is the difference between Mounjaro and Wegovy HD?

Mounjaro is tirzepatide (GIP/GLP-1 dual receptor agonist) and Wegovy HD is semaglutide 7.2 mg (GLP-1 receptor agonist). They have different active ingredients and slightly different side-effect profiles.

Is Mounjaro or Wegovy HD more effective for weight loss?

Head-to-head trial data favors tirzepatide-based medications (Mounjaro, Zepbound) over semaglutide-based medications (Ozempic, Wegovy) in average percent weight loss. SURMOUNT-1 reported ~20.9% mean weight loss on tirzepatide 15 mg; STEP 1 reported ~14.9% on semaglutide 2.4 mg over comparable timelines.

Can I switch between Mounjaro and Wegovy HD?

Switching between GLP-1 medications requires re-titration when crossing active ingredients (semaglutide ↔ tirzepatide). Always coordinate with your prescriber before switching.

Other GLP-1 head-to-head comparisons

More medication context

Tools and guides that pair with this comparison.

Affiliate disclosure: we earn commissions when readers sign up through our links. Editorial ranking is independent.